UBS has increased its price target for digital transformation leader Globant to $75, forecasting a period of stabilized, if modest, growth for the IT services sector next year despite near-term revenue headwinds.
Analyst firm Stifel has initiated coverage on sports data giant Genius Sports with a Hold rating, praising its foundational role in the online betting ecosystem but flagging a balanced risk-reward at current levels.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
The French government has intervened to stop satellite operator Eutelsat from selling its ground antenna assets, framing the move as a defense of European strategic autonomy against rivals like SpaceX's Starlink.
As demand for specialist education soars, private investors—from Abu Dhabi to private equity firms—are capitalizing on a strained system, drawing criticism for extracting profits from vulnerable children and cash-strapped councils.
With key self-assessment deadlines approaching, property investors must navigate a changed landscape of tax reliefs and allowable expenses to minimise their liabilities. Experts urge early preparation to avoid costly surprises.
A growing number of pensioners are being drawn into the self-assessment tax system as frozen thresholds clash with rising state pension payments. This guide explains who needs to file, key deadlines, and strategies to protect your retirement income.
Despite bearing the brunt of costly natural disasters, Asia-Pacific remains the world's least insured region, with a staggering $64 billion protection shortfall in 2024 alone, threatening economic stability and vulnerable communities.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
As global economic headwinds persist, UK investors are turning to dividend-paying stocks for portfolio resilience. We analyze three FTSE-listed companies with strong income credentials and growth potential for the coming year.
A sharp downturn in Bitcoin triggered a massive $1.7 billion liquidation event over 24 hours, with leveraged long positions bearing the brunt of the sell-off as market sentiment shifted.
PennyMac Mortgage Investment Trust (PMT) closed 2025 with robust earnings, driven by a dramatic expansion in its private-label securitization business. While this growth fueled returns, the company's correspondent lending segment faced pressure, and faster mortgage prepayments impacted servicing rights income.
Oshkosh Corporation reported full-year revenue of $10.4 billion and adjusted EPS of $10.79 for 2025. While projecting sales growth to approximately $11 billion in 2026, the company cautioned about near-term softness in its industrial access equipment segment and a significant $200 million tariff impact.
Amprius Technologies' shares have skyrocketed over 300% in the past year, driven by excitement around its silicon-anode battery technology. However, a deep dive into the company's financials reveals a significant valuation gap, raising questions about whether the stock's momentum has outpaced its fundamentals.
Janus Henderson Group (NYSE:JHG) finds itself at the center of a valuation debate. While some models peg the asset manager as modestly undervalued, a deeper cash flow analysis suggests a starkly different picture, leaving investors to weigh competing narratives amid industry headwinds.
PennyMac Mortgage Investment Trust (PMT) posted a strong Q4 profit of $52.36 million, defying a significant year-over-year revenue drop. This mixed performance has fueled a 12% stock rally over 90 days, raising questions about whether the current share price accurately reflects the company's future in a volatile mortgage market.
Fastly's stock has surged on the coattails of broader AI and edge computing optimism, but a closer look reveals a complex picture of short-term gains against longer-term struggles. As the market weighs future growth against persistent losses, investors are left questioning if the recent rally has legs.
Dynatrace shares have tumbled over 34% in the past year, significantly underperforming the broader software sector. A deep dive into valuation metrics, including discounted cash flow and peer comparisons, suggests the stock may be trading at a substantial discount. We examine the numbers and the narrative shaping investor sentiment.
